ClinicalTrials.gg
RecruitingNCT07806838Updated Nov 4, 2026

Effects of Dietary Supplements on Muscle Mass and Function While Using GLP-1 Medication

An interventional study of Whey Protein Supplementation and Maltodextrin Placebo Capsules in Obesity & Overweight, Muscle Mass and Strength and Muscle Function, sponsored by University of California, Los Angeles. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Prevention

Updated Nov 4, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Obesity by University of California, Los Angeles — 4 open to participants now, 5 under way, none of them phase 3. Obesity · University of California, Los Angeles.

Planned enrollment
16th of 27
75 · median 100
Started
2026
the only one that year
No phase
23 of 32
3 open now
Registered
32nd of 32
by date

Among the 32 studies in Obesity by University of California, Los Angeles, this one is the 16th largest by planned enrollment of the 27 interventional ones that give a count, is the only one that started in 2026, is one of 23 with no phase, and was the 32nd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 32 studies in Obesity by University of California, Los Angeles are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Obesity by University of California, Los Angeles, or all of them as a file.
02

Study summary

This pilot study will examine whether daily protein supplementation with or without a mixture of culinary spices can help preserve muscle mass and function in adults who are using GLP-1 medications for weight management.

The study will include 75 adults who recently started a GLP-1 medication and are experiencing weight loss. Participants will be randomly assigned to one of three groups: standard of care, protein supplementation plus placebo capsules, or protein supplementation plus mixed spice capsules. The study will last 6 months.

Researchers will compare changes in muscle mass and muscle function among the groups. Muscle mass will be measured using DEXA and D3-creatine enrichment. Muscle function will be assessed using walking, stair-climbing, and grip-strength tests. The study will also evaluate metabolic and inflammatory markers, body composition, dietary intake, physical activity, fatigue, sleep quality, quality of life, and other measures related to muscle health.

03

Conditions studied

  • Obesity & Overweight
  • Muscle Mass and Strength
  • Muscle Function
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥18 years of age at screening visit.
  2. >27 kg/m² with weight-related conditions OR BMI >30 kg/m².
  3. Taking any FDA-approved GLP-1 medication, daily oral or weekly injectable, started up to three months ago, and experiencing at least 1 lb of weight loss per week.
  4. Screening laboratory tests without significant abnormalities that might interfere with the study.

Exclusion criteria

Exclusion Criteria:

  1. Consume spices regularly >5 g/day.
  2. Allergy or sensitivity to spices, or history of allergy or anaphylaxis of any kind.
  3. Diagnosed with Type 2 diabetes.
  4. Vegans/vegetarians.
  5. Consuming protein, amino acid, or creatine supplements; occasional or infrequent use (1 serving per week or less) is allowed.
  6. Milk protein allergy.
  7. Severe lactose intolerance.
  8. Current diagnosis of alcoholism or substance addiction.
  9. Uncontrolled hypertension (systolic BP >170 or diastolic BP >100).
  10. Eating a high-fiber/polyphenol diet or taking medication or dietary supplements that interfere with the absorption of polyphenols.
  11. Frequently using prebiotics, probiotics, yogurt, and/or fiber supplements.
  12. Pregnant, breastfeeding, or unwilling to practice during study participation.
  13. Presence of a condition or abnormality that, in the opinion of the investigator, would compromise participant safety or data quality.
  14. Renal impairment measured as \<45 mL/min/1.73 m² (\<60 mL/min/1.73 m² in subjects treated with SGLT2i), according to the CKD-EPI creatinine equation as defined by KDIGO 2012.
  15. Any unstable medical conditions or terminal diagnosis.
  16. Unstable thyroid disease-not taking medication or medication dosage changed one or more times over the last 6 months. Stable thyroid disease on an unchanged prescription medication dose for ≥6 months is acceptable.
  17. Current use of insulin or oral medication of metformin, SU, SGLT2i, glitazone, or DPP4 as single-agent therapy or combination oral agents.
  18. Taking GLP-1 medications for more than 3 months.
  19. Have a medical implant or other metal implant, including a pacemaker.
  20. Unwilling to stay on a GLP-1 medication for 6 months or for the duration of study participation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
75 participants (estimated)

Study arms

  • No intervention
    Arm 1 - Standard of Care

    Participants will continue their prescribed GLP-1 medication and routine clinical management under the direction of their treating healthcare provider. The study will not determine GLP-1 medication selection, dosing, dose adjustments, or clinical management. Participants will receive standardized dietary/calorie and physical activity guidance and will complete the same study assessments and follow-up visits as participants in the intervention groups. They will not receive the study protein supplement, spice capsules, or placebo capsules.

  • Placebo comparator
    Protein Supplementation + Placebo

    Participants will receive protein supplementation with a goal of total protein intake of 1.2 g/kg lean body mass per day, based on baseline lean body mass measured by DEXA, plus placebo capsules containing 4 g of maltodextrin daily for 6 months. Participants will also receive standardized dietary/calorie and physical activity guidance.

    Dietary Supplement: Whey Protein Supplementation · Dietary Supplement: Maltodextrin Placebo Capsules

  • Experimental
    Protein Supplementation + Mixed Spices

    Participants will receive protein supplementation with a goal of total protein intake of 1.2 g/kg lean body mass per day, based on baseline lean body mass measured by DEXA, plus 4 g of mixed spice capsules daily for 6 months. The daily spice mixture contains 1.0 g turmeric, 1.5 g cinnamon, 0.5 g oregano, 0.5 g black pepper, 0.3 g sage, and 0.2 g thyme. Participants will also receive standardized dietary/calorie and physical activity guidance.

    Dietary Supplement: Whey Protein Supplementation · Dietary Supplement: Mixed Spice Capsules

Interventions

  • Dietary supplementWhey Protein Supplementation

    Participants will receive Nutrasumma 100% Whey Protein Isolate (unflavored), providing 20 g whey protein isolate per serving. The 20 g of protein from the shake will count toward the total daily protein goal of 1.2 g/kg lean body mass/day. The remaining protein target will be met through the participant's usual diet.

  • Dietary supplementMaltodextrin Placebo Capsules

    Participants will consume placebo capsules containing 4 g of maltodextrin daily for 6 months.

  • Dietary supplementMixed Spice Capsules

    Participants will consume 4 g of mixed spice capsules daily for 6 months. The daily mixture contains 1.0 g turmeric, 1.5 g cinnamon, 0.5 g oregano, 0.5 g black pepper, 0.3 g sage, and 0.2 g thyme.

06

What researchers measure

Primary outcomes

  1. Change in Muscle Mass Measured by DEXA

    Muscle mass will be assessed using dual-energy X-ray absorptiometry (DEXA). Change in muscle mass from baseline to 6 months will be compared among the three study groups.

    Time frame: Baseline, 3 months, and 6 months

  2. Change in Muscle Mass Measured by D3-Creatine Enrichment

    Muscle mass will be assessed using the D3-creatine (D3Cr) dilution method. Change in muscle mass from baseline to 6 months will be compared among the three study groups. Urinary D3-creatine enrichment will be measured by liquid chromatography with tandem mass spectrometry and used to estimate total body skeletal muscle mass.

    Time frame: Baseline and 6 months

Secondary outcomes

  1. Change in 400-Meter Walk Test Performance

    Muscle function will be assessed using the 400-meter walk test.

    Time frame: Baseline, 1 month, 3 months, and 6 months

  2. Change in Stair Climbing Test Performance

    Muscle function will be assessed using a stair climbing test.

    Time frame: Baseline, 1 month, 3 months, and 6 months

  3. Change in Grip Strength

    Grip strength will be measured using a handheld dynamometer and recorded in kilograms. The best of three trials for each hand will be used in the analysis.

    Time frame: Baseline, 1 month, 3 months, and 6 months

  4. Change in Mitochondrial Function

    Mitochondrial function will be assessed in peripheral blood mononuclear cells (PBMCs), including autophagy and mitochondrial assays.

    Time frame: Baseline, 3 months, and 6 months

  5. Change in Fasting Glucose

    Fasting glucose will be measured to assess glucose homeostasis.

    Time frame: Baseline, 3 months, and 6 months

  6. Change in Fasting Insulin

    Fasting insulin will be measured to assess insulin sensitivity.

    Time frame: Time Frame: Baseline to 6 months

  7. Change in C-Peptide

    Description: Fasting C-peptide will be measured as a marker of pancreatic beta-cell function.

    Time frame: Baseline, 3 months, and 6 months

  8. Change in Glucagon

    Description: Fasting glucagon will be measured as a metabolic marker.

    Time frame: Baseline, 3 months, and 6 months

  9. Change in Glucose-Dependent Insulinotropic Polypeptide (GIP)

    Fasting GIP will be measured to evaluate metabolic pathways related to glucose regulation.

    Time frame: Baseline, 3 months, and 6 months

  10. Change in High-Sensitivity C-Reactive Protein (hs-CRP)

    Description: High-sensitivity C-reactive protein will be measured as a marker of systemic inflammation.

    Time frame: Time Frame: Baseline, 3 months, and 6 months

  11. Change in Body Weight

    Time frame: Baseline, 1 month, 3 months, and 6 months

  12. Change in Body Composition by Bioelectrical Impedance Analysis

    Body composition will be assessed using an InBody bioelectrical

    Time frame: Baseline, 1 month, 3 months, and 6 months

  13. Change in Fatigue Assessed by PROMIS Fatigue Short Form 8a

    Fatigue will be assessed using the PROMIS Fatigue Short Form 8-item questionnaire.

    Time frame: Baseline, 1 month, 3 months, and 6 months

  14. Change in Quality of Life Assessed by SF-36

    Quality of life will be assessed using the 36-Item Short Form Health Survey (SF-36).

    Time frame: Baseline, 1 month, 3 months, and 6 months

  15. Change in Sleep Quality Assessed by Pittsburgh Sleep Quality Index (PSQI)

    Sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). The global PSQI score ranges from 0 to 21, with higher scores indicating poorer sleep quality.

    Time frame: Baseline, 1 month, 3 months, and 6 months

  16. Change in Dietary Energy and Macronutrient Intake

    Dietary energy and macronutrient intake will be assessed using 24-hour dietary recalls.

    Time frame: Baseline, 1 month, 3 months, 4.5 months, and 6 months

  17. Change in Physical Activity

    Physical activity will be monitored using step counts from participants' personal devices and self-reported physical activity recorded using MyNetDiary.

    Time frame: Baseline, 1 month, 3 months, 4.5 months, and 6 months

  18. Change in Gut Microbiome Composition

    Gut microbiome composition will be assessed using fecal samples

    Time frame: Baseline and 6 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Sep 2028, 22 months after the start.

Of 3,690 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 22 months is close to that.

Counting every sponsor, half of 3,853 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2026
First posted
Sep 8, 2026
StartActual
Oct 22, 2026was Sep 2026
Primary completionEst.
Sep 1, 2028
CompletionEst.
Sep 1, 2028
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 10, 2026→Oct 22, 2026 (actual)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Start date Sep 10, 2026→Oct 22, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07806838
Responsible party
Zhaoping Li (Professor of Medicine and Chief of the Division of Clinical Nutrition at the University of California, Los Angeles, University of California, Los Angeles) — Principal investigator
First posted
Sep 8, 2026
Start date
Oct 22, 2026
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Nov 4, 2026

Study contacts

Hila Zelicha, PhD, MS, RD
Contact
uclanutrition@gmail.com
310-206-8292
Zhaoping Li
principal investigator · University of California, Los Angeles

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion